January 2007 in “Edward Elgar eBooks” TSPO might help treat anxiety and depression.
4 citations
,
February 2013 in “Revista De Saude Publica” Pill organizers and cutters can help with taking medication regularly but may affect the medication's effectiveness and safety.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
June 2017 in “Journal of The American Academy of Dermatology” Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
8 citations
,
January 2011 in “Korean Journal of Andrology” The doxazosin plus tamsulosin combination improved symptoms effectively with fewer side effects.
July 2017 in “OPAL (Open@LaTrobe) (La Trobe University)” High-throughput LC-MS screening is effective for finding new autotaxin inhibitors for asthma treatment.
18 citations
,
August 2011 in “Clinical Drug Investigation” Low-dose isotretinoin combined with pulsed azithromycin cleared acne in most patients, with mild side effects.
11-oxyandrogens are linked to excess hair growth in PCOS, but don't help diagnose it.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
February 2006 in “Inpharma Weekly”
May 2025 in “Experimental Dermatology” Triphenylphosphine oxide can increase oil production and reduce inflammation in skin cells without affecting TRPM5.
1 citations
,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
December 2021 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature”
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
44 citations
,
November 2022 in “Frontiers in Immunology” TLR-targeted therapies show promise in cancer treatment by helping destroy tumors.
September 2023 in “Journal of the American Academy of Dermatology” 1 citations
,
November 2024 in “Neuro-Oncology” Temozolomide can cause severe bone marrow suppression, leading to life-threatening complications.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
10 citations
,
August 2020 in “Drug metabolism and drug interactions” The NUDT15 gene variant causes severe side effects from azathioprine in some Indian patients.
January 2026 in “GSC Biological and Pharmaceutical Sciences” Adapalene, Diosmin, and Azelastine could be repurposed to treat onchocerciasis.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
December 2017 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” JAK inhibitors show promise for treating Alopecia Areata, while statins are not recommended.
September 2023 in “Journal of the American Academy of Dermatology” Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
9 citations
,
April 2024 in “The Oncologist” Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
January 2012 in “Medizinisch Wissenschaftliche Verlagsgesellschaft eBooks”